EX-1
from SC 13D/A
3 pages
The Undersigned Understands That Morgan Stanley & Co. LLC (“Morgan Stanley”) and J.P. Morgan Securities LLC (“J.P. Morgan”) Propose to Enter Into an Underwriting Agreement (The “Underwriting Agreement”) With Synageva Biopharma Corp., a Delaware Corporation (The “Company”), Providing for the Public Offering (The “Public Offering”) by the Several Underwriters, Including Morgan Stanley and J.P. Morgan (The “Underwriters”), of Shares (The “Shares”) of the Company’s Common Stock, $0.001 Par Value Per Share (The “Common Stock”)
12/34/56
EX-1
from SC 13D/A
8 pages
Reference Is Hereby Made to the $160,000,000 Aggregate Principal Amount of the 4.75% Convertible Senior Notes Due 2015 (The “Notes”) of Incyte Corporation (The “Company”) Which Baker/Tisch Investments, L.P., Baker Bros. Investments II, L.P., 667, L.P., Baker Brothers Life Sciences, L.P. and 14159, L.P. (Collectively, the “Baker Brothers”) Have Agreed to Purchase. Capitalized Terms Used Herein and Not Otherwise Defined Shall Have the Meaning Set Forth in the Indenture Relating to the Notes by and Between the Company and U.S. Bank National Association, as Trustee, to Be Dated as of Closing Date of the Sale and Issuance the Notes (The “Indenture”). in Consideration of the Mutual Covenants and Agreements of the Parties Herein, the Baker Brothers and the Company Agree as Follows
12/34/56
EX-1
from SC 13D/A
1 page
Exhibit 1 Agreement in Accordance With Rule 13d-1(k)(1) Under the Securities Exchange Act of 1934, as Amended, the Undersigned Hereby Agree That This Statement on Schedule 13d Relating to the Common Stock, No Par Value, of Anormed Inc. Is Being Filed With the Securities and Exchange Commission on Behalf of Each of Them. January 26, 2006 By: /S/ Julian C. Baker Julian C. Baker By: /S/ Felix J. Baker Felix J. Baker
12/34/56
EX-1
from SC 13D/A
1 page
Exhibit 1 Agreement in Accordance With Rule 13d-1(k)(1) Under the Securities Exchange Act of 1934, as Amended, the Undersigned Hereby Agree That This Statement on Schedule 13d Relating to the Common Stock, No Par Value, of Anormed, Inc. Is Being Filed With the Securities and Exchange Commission on Behalf of Each of Them. January 16, 2006 By: /S/ Julian C. Baker Julian C. Baker By: /S/ Felix J. Baker Felix J. Baker Page 8 of 10 Pages
12/34/56
EX-1
from SC 13D
1 page
Exhibit 1 Agreement in Accordance With Rule 13d-1(k)(1) Under the Securities Exchange Act of 1934, as Amended, the Undersigned Hereby Agree That This Statement on Schedule 13d Relating to the Common Stock, $0.01 Par Value, of Biocryst Pharmaceuticals, Inc. Is Being Filed With the Securities and Exchange Commission on Behalf of Each of Them. October 13, 2005 By: /S/ Julian C. Baker Julian C. Baker By: /S/ Felix J. Baker Felix J. Baker Page 8 of 8
12/34/56
